Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.40 |
| ▸ | CDC7 | O00311 | 3/20 | 0.39 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31735405 | 1.00 | PRKCI (0.49) | PRKCIMAPTBRPF1CYP19A1ROCK1 | |
| SCHEMBL29755944 | 0.87 | PRKCI (0.57) | PRKCIMAPTBRPF1CYP19A1ROCK1 | |
| SCHEMBL257517 | 0.85 | PRKCI (0.55) | PRKCIMAPTBRPF1ROCK1KCNH2 | |
| SCHEMBL15712437 | 0.82 | SMN1; SMN2 (0.55) | PRKCIMAPTBRPF1KCNH2FGFR1 | |
| SCHEMBL2264468 | 0.82 | MAPT (0.48) | PRKCIMAPTBRPF1CYP19A1CDC7 | |
| SCHEMBL30364924 | 0.82 | MAPT (0.48) | PRKCIMAPTBRPF1CYP19A1CDC7 | |
| Hydrochloric Acid SCHEMBL6654905 | 0.81 | MAPT (0.47) | PRKCIMAPTBRPF1CYP19A1CDC7 | |
| Hydrochloric Acid SCHEMBL6656724 | 0.81 | MAPT (0.47) | PRKCIMAPTBRPF1CYP19A1CDC7 | |
| SCHEMBL30241476 | 0.80 | KCNH2 (0.54) | PRKCIBRPF1CYP19A1CDC7CDK2 | |
| SCHEMBL16862145 | 0.80 | KCNH2 (0.54) | PRKCIBRPF1CYP19A1CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490064-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | Pharmacia Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |
| WO-2025245484-A1 | FOXN1 ACTIVATORS | THYMOFOX INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-3604306-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2003068230-A1 | SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE | PHARMACIA CORPORATION (US) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003062227-A1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | disclosed |
| US-6235758-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-5990133-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | PRKCI 313/4885MAPT 1689/4885BRPF1 3144/4885 |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | HTR5A, HTR2C, HTR1A | PRKCI 4653/4885MAPT 1035/4885BRPF1 3513/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | PRKCI 313/4885MAPT 1689/4885BRPF1 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.